Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs neostigmine for deep neuromuscular block recovery in laparoscopic radical gastrectomy
ChiCTR2300072327Phase 4Recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Jun 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of Sugammadex in gastric cancer (GC) (2 arms), sponsored by Shanxi Cancer Hospital. Primary endpoints: Time of tracheal extubation, Recovery time of TOF ratio ≥ 0.9 and 1 more. Started Jun 2023; status: recruiting.
02
Drugs
Sugammadex
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR2300072327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072327.